Layoffs at FibroGen
- Layoff events
- 2
- verified and sourced
- Roles reported
- At least 104
- events with no figure are not in this number
- Announced between
- Jul 2023 to Jul 2024
- Reported by
- Fierce Biotech and U.S. Securities and Exchange Commission
This page records what we could verify and source. It is not a complete record of every job cut at FibroGen: a layoff nobody published and nobody sent us is a layoff that is not on this page.
| Company | What happened | Roles reported | Share of staff | Where | Announced | Sources |
|---|---|---|---|---|---|---|
| FibroGen |
Pipeline setback
FibroGen announced a 75% reduction of its U.S. workforce after two late-stage cancer trials failed and the company stopped investment in pamrevlumab. |
Not known | 75% | United States |
1 source for FibroGen |
|
| FibroGen |
Pipeline setback
FibroGen announced a restructuring expected to eliminate approximately 104 U.S. positions, about 32% of its U.S. workforce, after multiple clinical setbacks. |
104 | Not known | United States |
1 source for FibroGen |
Where this comes from
Every cut listed for FibroGen was entered by a person who checked it against a filing or a named report. Nothing is scraped and nothing publishes itself. What is not here is what we have not verified, not what did not happen.
Spotted something wrong or missing about FibroGen? Tell us on our Discord and we will check it.